168 related articles for article (PubMed ID: 35802214)
21. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract][Full Text] [Related]
22. G3 GEP NENs category: are basic and clinical investigations well integrated?
Milione M; Fazio N
Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
25. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
26. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?
Merola E; Zandee W; de Mestier L; Klümpen HJ; Makulik K; Geboes K; van Velthuysen ML; Couvelard A; Cros J; van Eeden S; Hoorens A; Stephenson T; Zajęcki W; de Herder W; Munir A
Neuroendocrinology; 2021; 111(1-2):170-177. PubMed ID: 32155627
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
[TBL] [Abstract][Full Text] [Related]
28. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
[TBL] [Abstract][Full Text] [Related]
29. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
31. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
32. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
33. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
34. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis.
Krieg S; Roderburg C; Fung S; Luedde T; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2235-2246. PubMed ID: 35428913
[TBL] [Abstract][Full Text] [Related]
35. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
Liang Y; Yu XJ; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
[TBL] [Abstract][Full Text] [Related]
36. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
37. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
38. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
39. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
40. Radioligand Therapy with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Mróz A; Żmudzki W; Kamiński G
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
